Loading…
Anixa Biosciences, Inc. is projected to rise to $2.96 by 2027, a +12% move from its current price of $2.65. ANIX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.59 | $2.65 | $2.71 | -0.03% |
| May 30 | $2.56 | $2.65 | $2.74 | -0.05% |
| May 31 | $2.54 | $2.65 | $2.76 | -0.08% |
| Jun 1 | $2.53 | $2.65 | $2.77 | -0.11% |
| Jun 2 | $2.51 | $2.65 | $2.79 | -0.13% |
| Jun 3 | $2.50 | $2.65 | $2.80 | -0.16% |
| Jun 4 | $2.49 | $2.65 | $2.81 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.49 | $2.65 | $2.81 | -0.19% |
| Week 2 | $2.42 | $2.64 | $2.88 | -0.38% |
| Week 3 | $2.37 | $2.64 | $2.93 | -0.56% |
| Week 4 | $2.33 | $2.63 | $2.97 | -0.75% |
| Week 5 | $2.29 | $2.63 | $3.01 | -0.94% |
| Week 6 | $2.26 | $2.62 | $3.04 | -1.13% |
| Week 7 | $2.23 | $2.62 | $3.07 | -1.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Anixa Biosciences, Inc. is a biotechnology company focused on oncology, developing therapies and vaccines that address critical unmet needs in cancer care.
Its therapeutics programs include liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, and a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer.
The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Anixa Biosciences, Inc. (ANIX) is a healthcare stock with a current price of $2.79 and a market cap of $93.54M. It is ranked 4260 by market capitalization among listed equities.
The current price and market position sit against a long-range forecast that projects gradual upside over time. The 2026 forecast shows a min of $2.50, an avg of $2.79, and a max of $3.47 with 0% ROI and a NEUTRAL sentiment; subsequent years show rising averages and higher ROIs, culminating in a 2050 avg of $17.57 and a max of $30.68 with a 529.6% ROI and a BULLISH sentiment.
A major floor 12.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 18.5% above — a clean break opens room to run.
A major ceiling 24.7% above — clearing it would confirm fresh momentum.
Key ANIX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANIX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.73 | Sell | $2.72 | Sell |
| MA 10 | $2.77 | Sell | $2.77 | Sell |
| MA 20 | $2.89 | Sell | $2.83 | Sell |
| MA 50 | $2.82 | Sell | $2.88 | Sell |
| MA 100 | $2.93 | Sell | $3.00 | Sell |
| MA 200 | $3.34 | Sell | $3.14 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.73 | Neutral |
| Stoch RSI (14) | 4.98 | Buy |
| CCI (20) | -130.70 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -11.67 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.08 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 30.14 | Neutral |
| Momentum (10) | -0.30 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 2.72 | Sell |
| ADX (14) | 12.98 | Neutral |
| ATR (14) | 0.07 | Info |
30-day technical picture:
- Sentiment: BEARISH
- RSI14: 50
- SMA50: $2.83
- SMA200: $3.34
- Support: $2.67
- Resistance: $3.14
- 30-day range: $2.39 to $3.25
This near-term setup suggests price action is contained within a tight range around key moving averages, with a defined support and resistance boundary.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.50 | $2.65 | $3.28 | 0% | Neutral | |
| $2.39 | $2.96 | $3.88 | +12% | Neutral | |
| $2.83 | $3.59 | $4.84 | +35% | Bullish | |
| $3.05 | $3.95 | $5.47 | +49% | Bullish | |
| $3.21 | $4.22 | $5.96 | +59% | Bullish | |
| $3.29 | $4.39 | $6.32 | +66% | Bullish | |
| $3.41 | $4.63 | $6.76 | +75% | Bullish | |
| $3.48 | $4.77 | $7.08 | +80% | Bullish | |
| $3.68 | $5.12 | $7.70 | +93% | Bullish | |
| $4.54 | $6.38 | $9.72 | +141% | Bullish | |
| $5.23 | $7.76 | $12.48 | +193% | Bullish | |
| $10.01 | $16.27 | $28.33 | +514% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.50 | $2.65 | $3.10 | +0.00% |
| June 2026 | $2.22 | $2.59 | $3.10 | -2.12% |
| July 2026 | $2.19 | $2.59 | $3.13 | -0.32% |
| August 2026 | $2.22 | $2.63 | $3.21 | +1.84% |
| September 2026 | $2.17 | $2.59 | $3.18 | -1.73% |
| October 2026 | $2.10 | $2.51 | $3.11 | -2.93% |
| November 2026 | $2.13 | $2.56 | $3.18 | +1.80% |
| December 2026 | $2.18 | $2.63 | $3.28 | +2.71% |
Click any year to see its month-by-month ANIX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ANIX is projected to trade between $2.50 and $3.28, averaging $2.65 — a potential gain of 0% from today's $2.65. A consolidation phase looks the most probable path here.
Anixa Biosciences, Inc.'s 2027 outlook centres on $2.96, within a $2.39 to $3.88 range. That is up +12% on the projected 2026 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2028, ANIX could reach as high as $4.84, with a base case around $3.59 and support toward $2.83 — roughly +35% from $2.65. Buyers look set to stay in control over this stretch.
Expect ANIX to range from $3.05 to $5.47 through 2029. The $3.95 average target implies a +49% move from current prices. That is up +10% on the projected 2028 average. Momentum favours further upside here.
The ANIX price prediction for 2030 points to an average of $4.22 (low $3.21, high $5.96) — a potential gain of +59% on today's $2.65. Buyers look set to stay in control over this stretch.
In 2031, ANIX is projected to trade between $3.29 and $6.32, averaging $4.39 — a potential gain of +66% from today's $2.65. That is up +4% on the projected 2030 average. Momentum favours further upside here.
Anixa Biosciences, Inc.'s 2032 outlook centres on $4.63, within a $3.41 to $6.76 range. That is up +5% on the projected 2031 average. That marks a +75% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ANIX could reach as high as $7.08, with a base case around $4.77 and support toward $3.48 — roughly +80% from $2.65. Momentum favours further upside here.
Expect ANIX to range from $3.68 to $7.70 through 2034. The $5.12 average target implies a +93% move from current prices. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ANIX price prediction for 2035 points to an average of $6.38 (low $4.54, high $9.72) — a potential gain of +141% on today's $2.65. Momentum favours further upside here.
In 2040, ANIX is projected to trade between $5.23 and $12.48, averaging $7.76 — a potential gain of +193% from today's $2.65. That is up +22% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Anixa Biosciences, Inc.'s 2050 outlook centres on $16.27, within a $10.01 to $28.33 range. That is up +110% on the projected 2040 average. That marks a +514% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ANIX today (≈ 377.358491 ANIX) could be worth
$6,138.53
+$5,138.53 (+514%) by 2050 · US Dollar
Based on the average projected ANIX price of $16.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANIXwould be worth at today's price.
$1,000 invested in ANIX on May 27, 2025 (≈ 400 ANIX) would be worth
$1,060
+$60 (+6.0%) today · 1.06× · US Dollar
Based on a ANIX entry price of $2.5 vs. today's $2.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.73 | $970.7 | -2.9% |
| 1 month ago | $2.97 | $892.26 | -10.8% |
| 3 months ago | $3.04 | $871.71 | -12.8% |
| 6 months ago | $4.59 | $577.34 | -42.3% |
| 1 year ago | $2.5 | $1,060 | +6.0% |
| All time (5.0y) ago | $4.02 | $659.2 | -34.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANIX forecast.
Our base-case forecast reaches $5.30 around 2035.
Implied market cap at $5.30: $177.7M
Multi-year forecast snapshot: the model shows a path of gradual appreciation with strong upside potential later in the horizon. For 2026 the min, avg, and max prices are $2.50, $2.79, and $3.47, respectively, with a 0% ROI and a NEUTRAL sentiment. By 2027 the avg rises to $3.14 (min $2.52, max $4.11) with a 12.4% ROI and NEUTRAL sentiment.
From 2028 onward, the averages continue higher: 2028 avg $3.84, 2029 avg $4.20, 2030 avg $4.49, 2031 avg $4.72, 2032 avg $4.92, 2033 avg $5.09, 2034 avg $5.54, 2035 avg $6.85. The forecast remains bullish through 2040 (avg $8.39) and into 2050 (avg $17.57). The corresponding max prices reach $6.35 (2030), $10.46 (2035), $13.52 (2040), and $30.68 (2050), with ROIs rising to 60.9%, 145.6%, 200.6%, and 529.6% respectively.
These are estimates, not guarantees, and reflect market-implied forward-looking scenarios. The long-term path shows bullish potential, but investors should consider the inherent risks of small-cap biotechnology, including execution, clinical outcomes, and financing dynamics.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $4.49 with a max of $6.35 and a min of $3.41; the ROI is 60.9% and the sentiment is BULLISH.
The 2026 forecast is NEUTRAL with an avg of $2.79 and a 0% ROI. From 2027 onward, the outlook turns BULLISH with higher averages (e.g., 2027 avg $3.14; 2030 avg $4.49) and a long-term ROI reaching 529.6% by 2050, though these are estimates and not guarantees.
Yes. The forecast shows a max price of $10.46 in 2035, then higher maxes of $13.52 in 2040 and $30.68 in 2050.
Current price is $2.79. The 30-day range is $2.39 to $3.25.
The 2027 forecast shows an avg price of $3.14, with a min of $2.52, a max of $4.11, and an ROI of 12.4; sentiment is NEUTRAL.
Anixa Biosciences, Inc. Community Discussion
0Share your Anixa Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.